Monthly Healthcare Review October 2017 - BioEnterprise€¦ · Monthly Healthcare Review October...

Monthly Healthcare Review

October 2017

Company NameLast Financing

DateHQ Location Description

Last

Financing

Size

(Millions)

Lead Manager

InflaRx (IFRX) 13-Oct-17 Jena, Germany

Developer of therapeutics in the field of acute and chronic inflammation designed to

prevent organ dysfunction or limit progression into organ failure. 100.01

J.P Morgan, Leerink

Partners, BMO

Capital Markets

OptiNose (OPTN) 13-Oct-17 Yardley, PA

Developer of exhalation delivery systems capable of high and deep intranasal deposition of

medication. 120.00

BMO Capital

Market, Jefferies,

Piper Jaffray & Co.,

RBC Capital

Markets

The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.

IPOs

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape 1


October 2017

Company Name

Last

Financing

Date

HQ Location Round Description

Last

Financing

Size

(Millions)

Investor(s)

KSQ Therapeutics 2-Oct-17 Cambridge, MA Early Stage VC

Developer of an industrialized functional genomics engine that utilizes a

suite of proprietary CRISPR/Cas9 tools to identify novel pathways and

targets involved in oncology and immuno-oncology. 76.00

Flagship Pioneering,

Polaris Partners,

ARCH Venture

Partners, Alexandria

Equities

Locus Biosciences 2-Oct-17

Research Triangle

Park, NC Early Stage VC

Developer of sequence-specific precision antimicrobials for human

infectious diseases. 7.00

Tencent, North

Carolina Biotech

Center, Undisclosed

Investors

Peptide Logic 2-Oct-17 San Diego, CA

Accelerator/

Incubator

Owner and operator of a biopharmaceutical company that combines the

advantages of synthetic peptides and recombinant antibodies to create

innovative semi-synthetic biologics for the treatment of chronic pain. Undisclosed JLABS

Recombinetics 2-Oct-17 Saint Paul, MN Angel

Developer of gene editing technologies designed to manipulate

deoxyribonucleic acid samples to add and activate genes to solve problems

in biomedical research, livestock productivity, and animal-derived

biomaterials for use in medical applications. 0.08

Undisclosed

Investors

Cullinan Oncology 3-Oct-17 Boston, MA Early Stage VC

Developer of externally sourced cancer therapeutics intended to end a

drug program quickly if the early research suggests it won't work. 150.00

MPM Capital, F2

Ventures,

Undisclosed

Investors

Dominion Aesthetic

Technologies 3-Oct-17 San Antonio, TX Angel

Supplier of aesthetic medical devices designed to improve a patient's

interface and mobility. 1.60

Florida Institute for

the

Commercialization

of Public Research,

Undisclosed

Investors

Private Equity Placements and Venture Capital RoundsThe following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced

over the previous month.

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



Harbor MedTech 3-Oct-17 Irvine, CA Early Stage VC

Operator of a medicine company that provides wound healing and tissue

regeneration products. 5.37

Arsenal Capital

Management,

Undisclosed

Investors

InfiCure Bio 3-Oct-17 Umeå, Sweden

PE Growth/

Expansion

Developer of a pre-clinical mouse model that evaluates the effects of anti-

fibrotic drugs. Undisclosed

Partnerinvest Norr,

Northen Light

Capital, Vinnova

Invenra 3-Oct-17 Madison, WI Later Stage VC

Developer of a platform to screen peptides and proteins to discover and

develop new biologic drugs in areas like cancer, Alzheimer's disease, and

diabetes. 2.93

Undisclosed

Investors

Recursion

Pharmaceuticals 3-Oct-17 Salt Lake City, UT Early Stage VC

Provider of a drug discovery platform that uses biological tools to build

cellular disease models, enabling biologists to query and understand the

results of phenotypic screens, drug screens, and target discovery screens

with immediate access to raw images and underlying data. 60.00

Data Collective, Lux

Capital, Obvious

Ventures,

Advantage Capital,

Felicis, Epic, AME

Cloud Ventures,

Mubadala, Menlo

Ventures, Charles

River Ventures, Two

Sigma, Undisclosed

Investors

Thc Biomed

International 3-Oct-17 Kelowna, Canada PIPE

Producer of medical marijuana and provider of scientific research and

services related to the medical cannabis industry. 0.65 Alumina Partners

Imagin Medical (IME) 4-Oct-17 Vancouver, Canada PIPE

Developer of a technology intended for the early detection of cancer

through the use of endoscopes. 0.73

Undisclosed

Investors

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



Immatics 4-Oct-17 Tübingen, Germany Later Stage VC

Developer of immunotherapies designed to use the body's own immune

system to fight cancer. 58.00

Amgen, Wellington

Partners, dievini

Hopp BioTech, AT

Impf, Undisclosed

Investors

Koutif Therapeutics 4-Oct-17 Cleveland, OH Angel

Operator of a drug discovery company intended to fight inflammatory

diseases. 0.60

Undisclosed

Investors

OMEICOS

Therapeutics 4-Oct-17 Berlin, Germany Early Stage VC

Developer of a first-in-class small molecule therapy designed for the

treatment and prevention of atrial fibrillation. Undisclosed

Remiges Ventures,

Vesalius Biocapital

Partners and SMS

Group; SICAR,

High-Tech

Gründerfonds, KfW

Bankengruppe, IBB

Beteiligungsgesellsch

aft, The Falck

Revocable Trust,

Ascenion,

Undisclosed

Investors

Palleon Pharmaceuticals 4-Oct-17 Waltham, MA Early Stage VC

Developer of a biotechnology platform designed to offer a wider range of

rational combination therapies to treat cancer and tackle resistance to first-

generation immuno-oncology agents. 47.60

SR One, Pfizer,

Vertex Ventures

HC, Takeda

Ventures, AbbVie

Ventures

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



3T Biosciences 5-Oct-17 Palo Alto, CA Seed Round

Provider of medical research and development facilities that incorporate

synthetic biology and machine learning to discover novel targets in order to

cure cancer and other T-cell mediated diseases. 12.00

Thiel CapitaL, Asset

Management

Ventures, Sean

Parker, Undisclosed

Investors

Harmony Biosciences 5-Oct-17

Plymouth Meeting,

PA Early Stage VC

Developer of biopharmaceuticals designed to identify, develop, and

commercialize novel treatment options for patients with rare central

nervous system disorders. 270.00

Valor Equity

Partners, Fidelity

Management &

Research, HBM

Healthcare

Investments, Vivo

Capital, venBio,

Novo, Nan Fung

Capital, Paragon

Biosciences,

California Institute

for Quantitative

Biosciences

SCA Pharmaceuticals 5-Oct-17 Little Rock, AR

PE Growth/

Expansion

Developer of unit dosed oral syringes, drug shortage medications, and

compounded pharmaceutical products for hospitals, pharmacies, and

ambulatory surgery centers. Undisclosed

Enhanced Equity

Funds

Calcivis 6-Oct-17

Edinburgh, United

Kingdom Later Stage VC

Developer of a dental imaging system designed to transform the

assessment and management of demineralization associated with dental

caries and erosion. 1.63

Archangels Informal

Investment, Scottish

Enterprise, Julz,

Undisclosed

Investors

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



PanOptica 6-Oct-17 Bernardsville, NJ Early Stage VC

Provider of therapies for debilitating vision loss, age-related muscular

degeneration, and diabetic retinopathy. 11.00

SV Life Sciences

Advisers, Third

Rock Ventures

Qidni Labs 6-Oct-17 Kitchener, Canada

Accelerator/

Incubator

Developer of renal replacement therapy devices for patients with end-stage

renal disease. 0.55 43North

Sequella 6-Oct-17 Rockville, MD Later Stage VC

Developer of antibiotics for the treatment of tuberculosis and gastritis

infections. 0.63

Undisclosed

Investors

Blaze Bioscience 9-Oct-17 Seattle, WA Later Stage VC

Developer of a cancer surgery technology providing real-time, high

resolution visualization of cancer cells for surgeons to achieve better

resection of tumors while simultaneously preserving healthy tissues. 16.11

Undisclosed

Investors

MT-Medikals 9-Oct-17 Moscow, Russia Early Stage VC

Operator of a biotechnology firm intended to provide treatment of

multidrug-resistant tuberculosis. 0.19

Primer Capital,

Undisclosed

Investors

Sygnature Discovery 9-Oct-17

Nottingham, United

Kingdom

PE Growth/

Expansion Provider of integrated drug discovery and research services. Undisclosed

Phoenix Equity

Partners

Theraworx 9-Oct-17 Asheville, NC Later Stage VC

Provider of specialty care packs for peri-care prior to foley catheter

insertion and on-going foley maintenance. 41.57

Asgard Partners,

Undisclosed

Investors

Azura Ophthalmics 10-Oct-17 Tel Aviv, Israel Early Stage VC

Developer of innovative therapies for the treatment of meibomian gland

dysfunction. 16.00

TPG Biotech,

Brandon Capital,

OrbiMed, Ganot

Capital

Crescita Therapeutics 10-Oct-17 Mississauga, Canada

Secondary

Transaction -

Private

Provider of a portfolio of non-prescription skincare products and

prescription drug products for the treatment and care of skin conditions

and diseases. Undisclosed Knight Therapeutics

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



Engage Therapeutics 10-Oct-17 Summit, NJ Early Stage VC

Developer of a new drug-device combination therapy for people who

experience uncontrolled epileptic seizures. 23.60

TPG Biotech,

Adage Capital

Management,

Lifescivc, Lumira

Capital, Undisclosed

Investors

InjectSense 10-Oct-17 Emeryville, CA Angel

Developer of an injectable wireless pressure sensor designed to monitor

patient IOP profiles for glaucoma by focusing on minimally invasive

assistance to generate clinically actionable information for therapy

management and outcome. 9.84

Undisclosed

Investors

KalVista (KALV) 10-Oct-17

Porton Down,

United Kingdom PIPE

Developer of small-molecule pharmaceuticals designed for a variety of

hereditary diseases. 9.10 Merck & Co

Ribon Therapeutics 10-Oct-17 Lexington, MA Early Stage VC

Developer of novel therapeutics targeting monoADP-ribosylating PARPs

for cancer. 43.50

US Venture

Partners, Deerfield

Management, Osage

University Partners,

The Column Group,

Undisclosed

Investors

Wellesley

Pharmaceuticals 10-Oct-17 Newtown, PA Later Stage VC Developer of drugs for the treatment of nocturia. 3.78

Axella Bioventures,

Undisclosed

Investors

Asepticys 11-Oct-17 New Orleans, LA Early Stage VC

Developer of medical disinfection products that kill and deactivate

pathogenic organisms across all microbial kingdoms and are effective

across a broad spectrum of microbial pathogens. 2.65

Undisclosed

Investors

Biophytis (ALBPS) 11-Oct-17 Paris, France PIPE Developer of drugs for metabolic disorders and age-related diseases. 12.40

Undisclosed

Investors

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



GrowHealthy 12-Oct-17 Lake Wales, FL Corporate

Operator of a marijuana farm offering medical marijuana, clinics, and

pharmaceutical-grade medical marijuana cannabis-infused products. 6.00

iAnthus Capital

Management

Janpix 12-Oct-17

London, United

Kingdom Early Stage VC Devleoper of therapies to treat hematological tumors and glioblastomas. 17.70

Medicxi Ventures,

Undisclosed

Investors

LabGenius 12-Oct-17

London, United

Kingdom Angel

Provider of a closed-loop platform intended to develop a new generation

of biological products using artificial intelligence, automation, and synthetic

DNA. 2.77

Undisclosed

Investors

Realm Therapeutics

(RLM) 12-Oct-17 Malvern, PA PIPE

Develper of small molecule therapies for the treatment of inflammatory

diseases with potential applications in dermatology, ophthalmology, and

other diseases. 26.00

OrbiMed, BVF

Partners, RA Capital

Management,

Abingworth

BioEquities Master

Fund, Polar Capital

Techulon 12-Oct-17 Blacksburg, VA Angel

Operator of a biotechnology platform that facilitates delivery of nucleic

acids for a variety of therapeutic applications, enabling researchers to

develop a targeted approach to inhibit growth of common MDR bacteria

and new strains of bacteria. 0.20

Undisclosed

Investors

Thermedical 12-Oct-17 Waltham, MA Later Stage VC

Developer of a thermal ablation therapy designed to treat cancer and

cardiac arrhythmias. 8.75

Undisclosed

Investors

VirionHealth 12-Oct-17

Coventry, United

Kingdom Early Stage VC

Developer of biological antivirals created to offer improved therapeutics

for respiratory viral infections. 17.28 Abingworth

ENTvantage Dx 13-Oct-17 Austin, TX Early Stage VC

Developer of an in-office diagnostic test kit designed to determine the

cause of ear, nose, and throat illnesses. 3.30

Keiretsu Forum,

Undisclosed

Investors

FirstString Research 13-Oct-17 Mount Pleasan, SC Later Stage VC

Provider of therapeutics designed to engage in the translation of cell-cell

communication and cell-cell adhesion science into a pipeline of drugs for

wound healing and complex tissue regeneration. 6.58

Undisclosed

Investors

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



Prima-Temp 13-Oct-17 Boulder, CO Later Stage VC

Developer of a device designed to provide precise and accurate core body

temperature measurements. 5.43

Undisclosed

Investors

Quadron Capital (QCC) 13-Oct-17 Vancouver, Canada PIPE

Provider of ancillary equipment, products, and services designed and

structured to address the complex needs and requirements of authorized

cannabis industry participants. 0.81

Undisclosed

Investors

SlipChip 13-Oct-17 Chicago, IL Early Stage VC

Developer of a disruptive microfluidic platform designed to offer

quantitative and digital nucleic acid analysis. 28.94

Undisclosed

Investors

LambdaVision 16-Oct-17 Farmington, CT Early Stage VC

Developer of a protein-based, retinal implant technology that utilizes a

light-activated protein to stimulate the retinas of patients with impaired

vision or sight loss due to retinal degenerative diseases. 0.50

Connecticut

Innovations

Aperiomics 17-Oct-17 Ashburn, VA Seed Round

Developer and provider of a disease diagnosis technology that can

simultaneously test for all pathogens. 0.51

Pipeline Angels,

Chemical Angel

Network

Cydan 17-Oct-17 Cambridge, MA Early Stage VC

Operator of an orphan drug accelerator designed to accelerate therapies

through clinical, regulatory, and commercial development for treating

patients with more than 7,000 rare diseases with approximately 400

approved treatments. 34.00

New Enterprise

Associates,

Longitude Capital,

Pfizer Venture

Investments,

Alexandria Venture

Investments,

Lundbeckfond

Ventures

DiFusion Technologies 17-Oct-17 Austin, TX Angel

Developer of metallic ion therapeutic agents technology designed for

antimicrobial, cellular repair, tissue regeneration, bone growth, scaffold

construction, and increased angiogenesis. 3.47

Undisclosed

Investors

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



Forty Seven 17-Oct-17 Menlo Park, CA Early Stage VC Developer of next generation immuno-oncology therapies. 75.00

Wellington

Management, Clarus

Ventures,

Lightspeed Venture

Partners, Sutter Hill

Ventures, GV

Gemini Therapeutics 17-Oct-17 Cambridge, MA Early Stage VC

Developer of precision therapeutics created to treat genetically-defined dry

age-related macular degeneration and associated rare genetic diseases. 42.50

Atlas Venture,

Lightstone

Ventures, OrbiMed

Lumicell 17-Oct-17 Wellesley, MA Later Stage VC

Developer of an intraoperative imaging system that includes a margin-

targeted injectable imaging agent and hand-held imaging device that gives

surgeons real-time visual feedback of residual cancer in the tumor bed. 27.48

Kodiak Venture

Partners, Launch

Capital, BlueIO,

Sigmas Emerging

Markets,

Undisclosed

Investors

Mission Bio 17-Oct-17 San Francisco, CA Early Stage VC

Developer of technologies to analyze single cells within complex biological

systems designed to detect critical information not observable from bulk

sample analysis. 10.00

Mayfield Fund,

Keiretsu Forum,

Keiretsu Capital

TAI Diagnostics 17-Oct-17 Milwaukee, WI Early Stage VC

Developer of a non-invasive and highly sensitive diagnostic test designed

to monitor the health of transplanted organs. 1.77

Undisclosed

Investors

Critical Outcome

Technologies (COT) 18-Oct-17 London, Canada PIPE

Developer of targeted therapeutic products for ovarian and other

gynecological cancers that help restore normal cell signaling in cancer with

p53 mutations. 2.07

Undisclosed

Investors

CureVac 18-Oct-17 Tübingen, Germany Later Stage VC

Developer of mRNA-molecules for therapeutic and prophylactic vaccines

designed to instruct the human body to produce its own proteins to fight a

wide range of diseases. 53.64

Eli Lilly and

Company

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



Kairos BioMedical 18-Oct-17 Honolulu, HI Angel

Owner and operator of an evidence-based biomedical company that

discovers, develops, and commercializes immuno preventative and

therapeutic products in partnership with leading companies and

institutions. 0.18

Undisclosed

Investors

Miromatrix 18-Oct-17 Eden Prairie, MN Later Stage VC

Developer of a perfusion decellularization technology designed to

manufacture human organs for transplantation. 1.71

Undisclosed

Investors

Prenetics 18-Oct-17

Quarry Bay, Hong

Kong Later Stage VC

Developer of a pharmacogenomics platform designed to offer

personalized, predictive, and preventive treatments. 40.00

Beyond Ventures

and Alibaba

Entrepreneurs

Fund; Yuantai

Investment Partners,

MFUND, eGarden

Ventures

Seventh Sense

Biosystems 18-Oct-17 Medford, MA Later Stage VC

Developer of a blood collection device designed to make blood testing

more convenient and virtually painless. 12.50

Novartis, LabCorp

and Polaris Partners,

Ionis

Pharmaceuticals,

Flagship Ventures

Ambry Genetics 19-Oct-17 Aliso Viejo, CA

PE Growth/

Expansion

Operator of a genetics diagnostics company designed to provide a

comprehensive suite of genetic testing applications for inherited and non-

inherited diseases. 400.00

Innovation Network

Corporation of

Japan

Claret Medical 19-Oct-17 Santa Rosa, CA Later Stage VC

Developer of a cerebral protection system designed to reduce the risk of

stroke during transcatheter aortic valve replacement. 21.21

Lightstone

Ventures, Easton

Capital Investment

Group, HealthCor

Partners

Management,

Incept, Santé

Ventures

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



Helix BioPharma (HBP) 19-Oct-17

Richmond Hill,

Canada PIPE

Developer of an oncology platform technology designed to induce an

increase in pH locally at the site of cancerous cells in the body to create an

environment inhospitable to their continued growth and survival. 4.91

Undisclosed

Investors

Microbix Biosystems

(MBX) 19-Oct-17 Mississauga, Canada PIPE

Manufacturer and distributor of infectious disease antigens and biological

products for the global diagnostics industry, notably antigens used in

immunoassays or quality assurance and proficiency testing controls. 1.89

Undisclosed

Investors

Replicel Life Sciences

(RP) 19-Oct-17 Vancouver, Canada PIPE Developer of drugs intended for autologous cell therapies. 1.15

Undisclosed

Investors

Synthego 19-Oct-17 Redwood City, CA Early Stage VC Developer of a precision tool to automate genome engineering research. Undisclosed Intel Capital

Veritas Pharma (VRT) 19-Oct-17 Vancouver, Canada PIPE

Developer of innovative medicinal cannabis cultivars for specific disease

conditions such as chronic pain, emesis, and epilepsy. 2.61

Marapharm

Ventures,

Undisclosed

Investors

Hubei 377

Biotechnology

Company 20-Oct-17 Beijing, China

Secondary

Transaction -

Private

Manufacturer of biotechnological devices, including DNA and RNA

synthesis instruments, gene analyzers, synthesizers, amplifiers, protein

purifiers, automated workstations, and other related products. 15.90

Anhui Anke

Biotechnology

Prelude Therapeutics 20-Oct-17 Newark, DE Angel

Developer of medicines targeting chromatin function for the treatment of

cancers and rare diseases. 12.00

Undisclosed

Investors

RenovaCare (RCAR) 20-Oct-17 New York, NY PIPE

Developer of autologous stem cell therapies, including treatments that

target the skin, intended for regeneration of human organs. 2.30

Undisclosed

Investors

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



ADC Therapeutics 23-Oct-17

Epalinges,

Switzerland Early Stage VC

Developer of antibody and non-antibody drug conjugate products that

target hematological cancers and tumor cells. 200.00

Auven Therapeutics,

Wild Family Office,

AstraZeneca,

Redmile Group,

Undisclosed

Investors

Appili Therapeutics 23-Oct-17 Halifax, Canada Early Stage VC Developer of oral antibiotics for the treatment of infectious diseases. 3.06

Innovacorp,

Undisclosed

Investors

GeneCapture 23-Oct-17 Huntsville, AL Angel

Developer of medical diagnostic devices designed to detect and identify

pathogens. 0.17

Undisclosed

Investors

MYM Nutraceuticals

(MYM) 23-Oct-17 Vancouver, Canada PIPE

Provider of bio-pharmaceutical research services intended to produce

quality cannabis growing facilities and developer of high-end organic

medicinal marijuana supplements and topical products. 3.46

Undisclosed

Investors

Purigen Biosystems 23-Oct-17 Pleasanton, CA Early Stage VC

Developer of an anisotachophoresis chip for nucleic acid preparation to be

used for genomic analyses. 20.85

Roche Venture

Fund, Startx, 5AM

Ventures, Western

Investments Capital,

Undisclosed

Investors

Helixbind 24-Oct-17 Marlborough, MA Angel

Developer of a pathogen identification platform that offers rapid detection

and unequivocal identification of bloodstream infections direct from a

whole blood specimen and without the need for blood culture. 286.00

Undisclosed

Investors

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



ImmuneTarget 24-Oct-17 San Diego, CA Angel

Developer of a research platform for targeted therapies created to treat

cancers and autoimmune diseases. 0.86

Undisclosed

Investors

Proteon

Pharmaceuticals 24-Oct-17 Lodz, Poland Early Stage VC

Developer of bacteriophage-based products used as an alternative to

antibiotics in combating pathogenic bacteria, including antibiotic resistant

microbes. Undisclosed Aqua-Spark

Sirona Biochem (SBM) 24-Oct-17 Vancouver, Canada PIPE

Developer of a proprietary platform technology with a specialization in the

stabilization of carbohydrate molecules for the cosmetic and drug

discovery industries. 0.64

Undisclosed

Investors

YmAbs 24-Oct-17 New York, NY Early Stage VC

Developer of immunotherapycancer treatments created to drive multiple

product candidates in select solid tumor cancers. 50.00

HBM Healthcare

Investments,

Undisclosed

Investors

Gemneo Bioscience 25-Oct-17 Scottsdale, AZ Angel

Developer of an immune cell profiling technology designed to provide

more optimal cancer treatments and help physicians better understand and

tailor treatments around individual patient's disease and immune responses. 0.10

Undisclosed

Investors

Waverley Pharma

(WAVE) 25-Oct-17 Winnipeg, Canada PIPE Developer of small molecule therapeutics for the treatment of cancer. 4.47

Undisclosed

Investors

Celsee Diagnostics 26-Oct-17 Plymouth, MI Later Stage VC

Developer of a fully-automated circulating tumor cell detection system that

has the ability to analyze biomarkers at a single-cell level at the site of

collection. 7.91

Undisclosed

Investors

Whistler Medical

Marijuana 26-Oct-17 Whistler, Canada Angel Producer of organic medical marijuana. 0.40

Undisclosed

Investors

Source: Pitchbook



October 2017

Company Name

Last

Financing

Date


Last

Financing

Size

(Millions)

Investor(s)



BioTuring 27-Oct-17 San Diego, CA Angel

Developer of a cloud-based software platform utilizing machine learning

and bioinformatics algorithms to store and analyze genomic data. 1.02

Undisclosed

Investors

Kymera 30-Oct-17 Cambridge, MA Early Stage VC

Operator of a biotech firm enaging in the field of targeted protein

degradation to access the body's innate protein recycling machinery. 30.00

Atlas Venture, Lilly

Ventures, Amgen

Ventures

Maxwell MRI 30-Oct-17 Brisbane, Australia Early Stage VC

Provider of a prostate cancer detection and diagnosis platform that

combines deep learning with modern medical imaging and integrates with

existing PACS systems. Undisclosed

Main Sequence

Ventures

Personal Genome

Diagnostics 30-Oct-17 Baltimore, MD Later Stage VC

Developer of cancer genome testing products designed to help in

identifying tumor mutations with accuracy by identifying alterations in

complex cancer genomes. 65.37

Undisclosed

Investors

Ribometrix 31-Oct-17 Greenville, NC Seed Round

Developer of RNA-targeted small molecule drugs created for the

treatment of rare, orphan, and unmet human diseases. 7.50

SV Health Investors,

Hatteras Venture

Partners, AbbVie

Ventures, MP

Healthcare Venture

Management,

Alexandria Venture

Investments

Source: Pitchbook



October 2017

Acquirer Target HQ Location Date DescriptionTransaction

Value (Millions)

Stallergenes Greer Medic Savoure Dutton, Canada 2-Oct-17

Provider of allergy immunotherapy products, including diagnostics and AIT

treatment products. Undisclosed

Abbott Laboratories Alere Waltham, MA 3-Oct-17

Manufacturer of consumer and professional medical diagnostic products designed

for the detection of diseases. 4600.00

Undisclosed Apicore US Somerset, NJ 3-Oct-17

Developer and manufacturer of specialty active pharmaceutical ingredients and

pharmaceuticals. 105.00

Gilead Sciences Kite Pharma Santa Monica, CA 3-Oct-17

Developer of active cancer immunotherapies that express either a chimeric

antigen receptor or a T-cell receptor, addressing both hematological and solid

tumor cancers. 12000.00

Fagron All Chemistry Sao Paulo, Brazil 5-Oct-17

Distributor of pharmaceutical raw materials and provider of testing and

microbiological analysis. Undisclosed

Medtronic

Animas (Insulin

pump business) Wayne, PA 5-Oct-17

Manufacturer and developer of medicines and vaccines for the treatment of

diabetes. Undisclosed

Prescient Medicine PGxl Laboratories Louisville, KY 5-Oct-17

Provider of pharmacogenetics services engaged with the development of

personalized medicine at the level of discovery, assay development, and clinical

testing. Undisclosed

Emergent BioSolutions ACAM2000 Paris, France 6-Oct-17

Developer of a vaccine for active immunization against smallpox disease for

persons determined to be at high risk for smallpox infection. 125.00

First Coin Capital

Bradmer

Pharmaceuticals

(BMR.H) Toronto, Canada 10-Oct-17 Provider of new and innovative cancer therapies. Undisclosed

Kerry Group Ganeden Biotech

Mayfield Heights,

OH 11-Oct-17

Developer of patented probiotic ingredients designed for making over-the-counter

probiotic products. Undisclosed

Lupin

Symbiomix

Therapeutics Newark, NJ 11-Oct-17

Developer of a potent, next-generation, 5-nitroimidazole antibiotic with enhanced

pharmacokinetic properties that makes efficacious and well-tolerated delivery in a

single dose, enabling patients to get treated from bacterial vaginosis. 150.00

Erkafarm

Rosta Group

(Certain

Subsidiaries)

Saint Petersburg,

Russia 12-Oct-17 Wholesaler and retailer of pharmaceutical products. Undisclosed

Priority Aviation Telluride Health Telluride, CO 12-Oct-17 Operator of a medical cannabis enterprise. Undisclosed

Mergers and AcquisitionsThe following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous

month.

Source: Pitchbook



October 2017

Acquirer Target HQ Location Date DescriptionTransaction

Value (Millions)

Mergers and AcquisitionsThe following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous

month.

Karo Pharma Weifa Oslo, Norway 12-Oct-17

Provider of pharmaceutical drugs for menstrual pain, headaches, swelling and pain

in muscles and joints, wound treatment, and other areas. 163.61

Bracco Imaging SurgVision Harde, Netherlands 18-Oct-17

Provider of a molecular surgical imaging technology designed to discriminate

between healthy and cancerous tissue. Undisclosed

Fortive Landauer (LDR) Glenwood, IL 19-Oct-17

Provider of integrated radiation safety products and services intended to improve

public health and safety by advancing research, technology, and services related to

radiation measurement and medical physics. 770.00

Catalent

Catalent

Bloomington Bloomington, IN 23-Oct-17

Provider of advanced delivery technologies and development solutions for drugs,

biologics, and consumer health products 950.00

Finch Therapeutics Crestovo Cambridge, MA 23-Oct-17

Developer of an orally-administered microbiome designed to deliver novel

therapeutics that involves transfer of good bacteria from one person's gut to

another. Undisclosed

Clinigen Group

International

Medical

Management

Company Minato, Japan 23-Oct-17

Supplier of unlicensed medicines, pharmaceuticals, medical equipment, and

cosmetics. Undisclosed

Grey Cloak Tech Eqova Life Sciences Denver, CO 24-Oct-17

Developer of clinical grade full spectrum hemp oil products developed in

compliance with cGMP, formulated by medical experts with natural ingredients

combined together, and are sold under the CannaBio brand via partnerships with

licensed medical practitioners to use with their patients. Undisclosed

Merck & Co Rigontec Munich, Germany 26-Oct-17 Developer of RNA-based immuno-therapeutics for cancer and viral diseases. 553.06

Maricann Group

NanoLeaf

Technologies Toronto, Canada 27-Oct-17

Operator of a biotechnology company that processes licensing rights to a number

of globally patented technologies that provide proven pharmaceutical,

nutraceutical, cosmetic, and functional beverage drug delivery formulations. 31.31

Source: Pitchbook


Monthly Healthcare Review October 2017 - BioEnterprise€¦ · Monthly Healthcare Review October...

Documents

Transcript of Monthly Healthcare Review October 2017 - BioEnterprise€¦ · Monthly Healthcare Review October...